Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Marinus Pharma CS
(NQ:
MRNS
)
1.410
-0.030 (-2.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharma CS
< Previous
1
2
3
4
5
6
7
8
9
Next >
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
April 17, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss
April 16, 2024
Marinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review.
Via
Benzinga
The Latest Analyst Ratings For Marinus Pharma
April 16, 2024
Via
Benzinga
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
April 15, 2024
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
April 15, 2024
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Via
InvestorPlace
Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights
March 26, 2024
Via
Benzinga
Leverage Shares -3x Short Moderna (MRNA) ETP Securities: Q4 Earnings Insights
March 05, 2024
Via
Benzinga
Marinus Pharma's Earnings Outlook
March 04, 2024
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
April 15, 2024
Via
Benzinga
Why Are Stocks Up Today?
April 15, 2024
Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday!
Via
InvestorPlace
Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) is a Stock Spotlight on 1/5
January 05, 2024
Via
Investor Brand Network
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
April 15, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
DJT Stock Alert: Trump Media Plunges on Share Sale Panic
April 15, 2024
Trump Media & Technology stock is falling hard on Monday as investors react to a filing for a secondary offering of DJT shares.
Via
InvestorPlace
Topics
Government
Exposures
Political
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
April 15, 2024
Marinus Pharmaceuticals stock is falling on Monday with heavy trading of MRNS shares after posting an update on a Phase 3 trial.
Via
InvestorPlace
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
April 15, 2024
From
Schall Law
Via
GlobeNewswire
Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?
April 15, 2024
Marinus Pharmaceuticals provides updates on Phase 3 RAISE trial for refractory status epilepticus treatment with IV ganaxolone. With enrollment completion expected, topline results are anticipated by...
Via
Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
April 15, 2024
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 15, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 15, 2024
Via
Benzinga
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
April 15, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
March 27, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q4 2023
March 05, 2024
MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 05, 2024
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
February 21, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Earnings Scheduled For March 5, 2024
March 05, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
Via
Benzinga
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 20, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 16, 2024
From
Marinus Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.